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Abstract
Background: The results of observational studies evaluating and comparing the cardiovascular safety of glitazones,
metformin and sufonylureas are inconsistent.To conduct and evaluate heterogeneity in a meta-analysis of observational
studies on the risk of acute myocardial infarction (AMI) or stroke in patients with type 2 diabetes using non-insulin blood
glucose–lowering drugs (NIBGLD).
Methods: We systematically identified and reviewed studies evaluating NIBGLD in patients with type 2 diabetes indexed
in Medline, Embase, or the Cochrane Library that met prespecified criteria. The quality of included studies was assessed
with the RTI item bank. Results were combined using fixed- and random-effects models, and the Higgins I2 statistic was
used to evaluate heterogeneity. Sensitivity analyses by study quality were conducted.
Results: The summary relative risk (sRR) (95 % CI) of AMI for rosiglitazone versus pioglitazone was 1.13 (1.04–1.24)
[I2 = 55 %]. In the sensitivity analysis, heterogeneity was reduced [I2 = 16 %]. The sRR (95 % CI) of stroke for rosiglitazone
versus pioglitazone was 1.18 (1.02–1.36) [I2 = 42 %]. There was strong evidence of heterogeneity related to study quality in
the comparisons of rosiglitazone versus metformin and rosiglitazone versus sulfonylureas (I2≥ 70 %). The sRR (95 % CI) of
AMI for sulfonylurea versus metformin was 1.24 (1.14–1.34) [I2 = 41 %] and for pioglitazone versus metformin was 1.02
(0.75–1.38) [I2 = 17 %]. Sensitivity analyses decreased heterogeneity in most comparisons.
Conclusion/interpretation: Sulfonylureas increased the risk of AMI by 24 % compared with metformin; an imprecise
point estimate indicated no difference in risk of AMI when comparing pioglitazone with metformin. The presence of
heterogeneity precluded any conclusions on the other comparisons. The quality assessment was valuable in identifying
methodological problems in the individual studies and for analysing potential sources of heterogeneity.
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Background
Globally, about 1 billion people are overweight or obese,
which will cause an increase of epidemic proportions in
the number of persons with type 2 diabetes and cardio-
vascular disease. In 2011, 366 million people had been
diagnosed with diabetes, and the number is expected to
rise to 552 million by 2030. Most people with diabetes
live in the developing world, and this area will see the
greatest increase over the next 19 years [1].
Type 2 diabetes mellitus (T2DM) is characterised by
high blood glucose levels that cause eye, kidney, and nerve
complications and an increased risk for cardiovascular
disease. Most of the morbidity and mortality associated
with diabetes is due to cardiovascular disease; diabetes is
considered by some as a coronary heart disease risk–
equivalent condition [2]. Although this concept is contro-
versial [3], there is evidence that the risk equivalence
might hold at least for women [4].
Controversy has surrounded the cardiovascular safety
of some non-insulin blood glucose–lowering drugs
(NIBGLD), particularly sulfonylureas and thiazolidine-
diones. Rosiglitazone was removed from the market in
Europe and its use highly restricted in the United States
of America (US) after review of safety evaluations from
clinical trials suggested that its use increased the inci-
dence of acute myocardial infarction (AMI) [5]. This
and the premature termination of the ACCORD trial [6],
after observing an increase in cardiovascular mortality in
the group treated more aggressively, prompted the US
Food and Drug Administration (FDA) to revise its policy
for approving new drugs for T2DM; a two-step approach
ensuring cardiovascular safety is now required. Evidence
has led some to question rosiglitazone’s adverse cardio-
vascular safety profile [7–9]. Using observational data,
compared with metformin, sulfonylureas have been asso-
ciated with a 21 % increase in the risk of hospitalisation
for AMI, stroke, or death [10].
Meta-analyses of clinical trials and observational stud-
ies reviewing the risk of AMI and/or stroke associated
with the use of oral blood glucose–lowering drugs for
T2DM have been published [11–18]. However, previous
meta-analyses of observational studies have not investi-
gated the heterogeneity present in results and methods
of individual studies [11, 15, 16]. Heterogeneity, analysis,
important for meta-analyses of observational studies
[19], might explain inconsistencies among results of
individual studies.
This research was part of the Safety Evaluation of
Adverse Reactions in Diabetes (SAFEGUARD) project.
This report summarises the results of a systematic re-
view and meta-analysis of published observational stud-
ies on the risk of AMI and stroke in patients with
T2DM receiving treatment with NIBGLD, analysis of the
heterogeneity in study characteristics and results, and
evaluation of study quality as an explanatory factor for
statistical heterogeneity. We also provide results of drug
comparisons not reported in previous meta-analyses.
With the recent introduction in clinical practice of new
classes of NIBGLD such as dipeptidyl peptidase-4 inhibi-
tors, glucagon-like peptide-1 receptor agonists, and
sodium-glucose cotransporter-2 inhibitors, it becomes
crucial to evaluate the cardiovascular safety of older
NIBGLD (e.g., glitazones, metformin and sufonylureas)
before their use in clinical practice may change with the
introduction of the newer agents, and newer clinical
guidelines.
Methods
We conducted a systematic literature search in Medline,
Embase, and the Cochrane Library. The search was con-
ducted on November 11, 2011 (see Additional file 1),
and was limited to observational studies on humans
(systematic reviews, meta-analyses, original articles),
with no publication date or language restrictions for
blood glucose–lowering drugs (except insulin); outcomes
were AMI, stroke, and others reported elsewhere with
details on the literature search, study selection, and data
abstraction [20]. Studies including transient ischaemic
attack in the definition of stroke were excluded. Studies
including stable angina in the definition of AMI were ex-
cluded. We conducted an updated literature search in
September 2014, and the impact of additional studies
that were identified is reported in the discussion section.
We assessed the quality of each study included in the
systematic review using two tools, the Newcastle-Ottawa
Scale [21] and the RTI item bank (RTI-IB) on risk of
bias and precision [22]. We used a version of the RTI-IB
adapted to the research question with 31 items. It was
applied independently by two researchers who discussed
disagreements until reaching consensus, when necessary.
Possible responses for most items denoted high, unclear,
or low risk of bias. Additional details on the tool and
how the quality assessment was performed are reported
elsewhere [23].
Quantitative analysis was conducted using Review
Manager software version 5.2.3 [24]. Additional details
can be found elsewhere [20]. For each comparison with
at least three independent point estimates available,
summary relative risks (sRRs) and 95 % CIs for AMI and
stroke were estimated using both fixed- and random-
effects models. Forest plots were constructed based on
random-effects models, and between-study heterogen-
eity was assessed by graphical inspection and with the
Higgins I2 statistic, which describes the percentage of
between-study variability in effect estimates attributable
to true heterogeneity rather than chance. The Cochran’s
χ2 test of homogeneity and Tau2, estimating the
between-study variance, are also presented. For studies
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providing estimates for both monotherapy and com-
bined therapy, we selected the combined-therapy esti-
mate because in clinical practice most patients with
T2DM require combined therapy and because it would
include more patients (more precision). To explore
sources of heterogeneity, we implemented subgroup
analyses designed a priori [20], followed by sensitivity
analyses in which we excluded studies with high/unclear
risk of bias for more than 30 % of the items in the RTI-
IB. An additional sensitivity analysis examined the po-
tential impact of the rosiglitazone controversy on the
meta-analysis results by grouping the studies according
to whether the study period finished before or on 2007,
started after 2007, or included 2007, the year in which
the first studies showing an increased cardiovascular risk
associated with the use of rosiglitazone were published.
Publication bias was examined by visual evaluation of
funnel plots. The present report follows the MOOSE
(Meta-analysis Of Observational Studies in Epidemi-
ology) checklist [25] (see Additional file 1: Table 10e).
The present systematic review of published observa-
tional studies does not require ethics approval.
Results and discussion
Results
Figure 1 displays the study selection process. From the
44 studies selected for the systematic review, we identi-
fied 23 studies evaluating the risk of AMI and 8 studies
evaluating the risk of stroke. Of the 23 studies on AMI,
17 contributed to the meta-analysis [26–42], with five
drug comparisons: rosiglitazone versus pioglitazone
(n = 11 studies), rosiglitazone versus metformin (n = 7),
pioglitazone versus metformin (n = 4), rosiglitazone versus
sulfonylureas (n = 5), and sulfonylureas versus metformin
Fig. 1 Flow diagram of study identification and selection process. Note: No additional study was identified by checking reference lists of included
studies. Some studies contributed to more than one drug-drug comparison
Pladevall et al. BMC Cardiovascular Disorders  (2016) 16:14 Page 3 of 17
(n = 4). Of the 8 studies on stroke, 3 contributed to the
meta-analysis for the comparison of rosiglitazone versus
pioglitazone [26, 30, 41]. Table 1 displays the list of studies
excluded from the meta-analyses for AMI and stroke and
the reasons for exclusion.
Table 2 displays the main characteristics of the 17
studies evaluating the risk of AMI included in the
present meta-analysis. Of the 17 studies, 1 was a
case–control study and the rest were cohort studies
(3 included a nested case–control analysis). The ma-
jority of the studies defined the outcome based on hospi-
talisations. Most studies included the specific diagnosis
code for AMI (i.e., ICD-9 code 410 or ICD-10 codes I21
and I22) in their algorithms to identify cases of AMI;
Tzoulaki et al. [38] used Read codes, and Sauer et al. [37]
used the Minnesota Heart Study criteria to validate cases
of AMI in a field study. Six studies included only first-ever
AMI; 11 studies included first-ever AMI plus previous
AMI. The number of AMI events in each study ranged
from 39 to 15,917. The majority of studies included a
broad age range, while a few were restricted to those aged
65 years or older. The definition of exposure varied across
studies: 10 studies included only new users of the drugs
studied, and the remaining 7 studies included a combin-
ation of new and prevalent users. Thirteen studies in-
cluded patients from North America, 2 studies included
European patients, 1 study was conducted in Israel, and 1
in Taiwan. Most of the US studies used claims databases.
Table 2 displays the main characteristics of the 3 studies
evaluating the risk of stroke. All were cohort studies
comparing rosiglitazone versus pioglitazone [26, 30, 41].
The number of events ranged from 32 to 1,869. Two stud-
ies included only elderly subjects that were new users of
study medications, while the other study included all sub-
jects aged older than 17 years and both new and prevalent
users.
In Figs. 2 and 3, the left panel displays the random-
effects forest plot for the comparisons included in our
meta-analysis. Summary results of study quality assess-
ment with the RTI-IB are provided in the right panel.
Detailed results of the Newcastle-Ottawa Scale and the
RTI-IB for the 31 studies included in the systematic re-
view are in the Additional file 1. An overview of the ex-
perience with and a comparison of the two tools is
reported elsewhere [23].
Risk of AMI: rosiglitazone versus pioglitazone
The overall sRR (95 % CI) was 1.13 (1.04-1.24), and there
was evidence of substantial heterogeneity (I2 = 55 %)
(Fig. 2). With the RTI-IB, for AMI, 2 studies had a high/
unclear risk of bias for 30 % or more of the items assessed
[27, 29]; 2 more studies had a high/unclear risk of bias for
25 to 29 % of the items assessed [26, 40]. For stroke, 1
study had high/unclear risk of bias for 25 % or more of
the items assessed [26].
The sensitivity analyses showed that heterogeneity was
reduced when restricting the analysis to new users of rosi-
glitazone and pioglitazone (I2 = 37 %) (Table 3). Even larger
reductions in heterogeneity were obtained in the sensitivity
analysis excluding the two studies at high/unclear risk of
bias for 30 % or more of the items assessed (I2= 16 %). Het-
erogeneity was also markedly reduced in the subgroup sen-
sitivity analyses. The sRR did not change much in those
analyses and were around 1.10 in most cases, but the 95 %
CIs were more conservative; when the two high/unclear-
bias studies were removed from the first-ever and prior
AMI subgroup and the new users subgroup, the random-
effects CIs included the null effect (Table 3).
Of the 11 studies included in the AMI meta-analysis,
three reported estimates for monotherapy drug use: one
study reported estimates for rosiglitazone and pioglita-
zone as add-on therapy for metformin users [28], and
the rest reported estimates of comparisons in which both
rosiglitazone and pioglitazone groups allowed combined
treatment with other oral blood glucose–lowering drugs.
The monotherapy groups included fewer patients than the
combination-therapy groups because very rarely in clinical
practice are glitazones prescribed without adjuvant therapy.
Risk of stroke: rosiglitazone versus pioglitazone
The sRR (95 % CI) was 1.18 (1.02–1.36); there was no
strong evidence of heterogeneity (I2 = 42 %). The meta-
analysis evaluating the risk of stroke associated with the
use of rosiglitazone compared with pioglitazone included
Table 1 Reasons for exclusion of studies
Author,
year
Endpoint(s) Reason for exclusion
Chou, 2011
[52]
Stroke, AMI The definitions of both stroke and AMI were
deemed not eligible. This study included
transient ischemic attack in the definition of
stroke and stable angina in the definition of AMI.
Azoulay,
2010 [58]
Stroke Studies excluded due to reference groups
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3 cohort studies of combination therapy (Fig. 2). Two
studies used Medicare data and studied patients aged
65 years and older; 1 included patients aged 18 years or
older. None reported information on dose or duration.
Risk of AMI: rosiglitazone versus metformin
The overall sRR (95 % CI) was 1.42 (1.03–1.98) (Fig. 3), but,
there was strong evidence of heterogeneity (I2 = 86 %).
With the RTI-IB quality assessment, 2 studies had a high/
unclear risk of bias for 30 % or more of the items assessed
[27, 32]; and 1 more study had a high/unclear risk of bias
for 25 % or more of the items assessed [36].
Subgroup analyses showed that heterogeneity was
reduced when restricting the analysis to new users of
rosiglitazone and metformin (I2 = 55 %) (Table 4). Even
larger reductions in heterogeneity were obtained in the
sensitivity analyses excluding the two studies at high/un-
clear risk of bias for 30 % or more of the items assessed
(I2 = 0 %). The sRR decreased in the subgroup analysis
(new users) to 1.29 and to 1.13 in the overall sensitivity
analysis; the null effect was included in the subgroup
analyses random-effects 95 % CI and the overall sensitiv-
ity analysis random- and fixed-effects 95 % CIs.
All 7 studies included in the meta-analysis used a co-
hort design, but 1 study performed a nested case–con-
trol analysis. Only 1 study was restricted to first-ever
events. Of the 7 studies, 5 included only new users of
the drugs studied, 4 reported estimates only for mono-
therapy drug use, 1 reported estimates only of compari-
sons in which the rosiglitazone and pioglitazone groups
allowed combination treatment with other oral blood
glucose–lowering drugs, and 2 provided estimates for
both monotherapy and combination therapy. Only 1
study provided results by exposure duration.
Risk of AMI: pioglitazone versus metformin
The sRR (95 % CI) was 1.02 (0.75–1.38), and there was
no evidence of significant heterogeneity in a meta-
analysis of 3 studies (I2 = 17 %). Four studies were avail-
able for this comparison (Fig. 3); however, the 95 % CI
reported by Dormuth et al. [28] did not result in an es-
timable standard error and therefore the study could not
be included in the meta-analysis.
Risk of AMI: rosiglitazone versus sulfonylureas
The sRR (95 % CI) was 0.99 (0.78–1.25), with strong evi-
dence of heterogeneity for this comparison (I2 = 70 %)
Fig. 2 Relative risk of acute myocardial infarction and stroke in rosiglitazone users compared with pioglitazone users. AMI, acute myocardial
infarction; IV, inverse variance. Red bars, percentage of items in the RTI item bank indicating high risk of bias; yellow bars, percentage of items at
unclear risk of bias. Items with low risk of bias not shown. Denominators indicate the number of items evaluated for each study.
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(Fig. 3 and Additional file 1: Table 8e). Five studies were
available for meta-analysis. In the sensitivity analysis that
excluded the high/unclear-bias studies [27, 32], hetero-
geneity was markedly reduced (I2 = 0 %) and the sRR (95
% CI) decreased to 0.82 (0.69–0.98).
Risk of AMI: sulfonylureas versus metformin
The sRR (95 % CI) was 1.24 (1.14–1.34) and evidence of
heterogeneity was moderate (I2 = 41 %). Four studies
were available for this comparison (Fig. 3, Additional file
1: Table 9e); all analysed sulphonylureas as a group and
some also reported on individual agents. Individual
agents in the evaluated studies were either first- or
second-generation sulphonylureas. For our analysis, we
included the reported RR for second-generation sulfo-
nylureas as they were the most frequently used. Three of
the four studies [28, 31, 38] provided specific data for
the comparison of glyburide versus metformin. When
Fig. 3 Relative risk of acute myocardial infarction in users of blood glucose–lowering medications. IV, inverse variance. Red bars, percentage of
items in the RTI item bank indicating high risk of bias; yellow bars, percentage of items at unclear risk of bias. Items with low risk of bias not
shown. Denominators indicate the number of items evaluated for each study. Rosiglitazone versus metformin: Tzoulaki et al. [38] contributed the
relative risk reported for combination therapy; for Loebstein et al. [35], the combination-therapy estimate was not estimable. Sulfonylureas versus
metformin: Tzoulaki et al. [38] contributed the estimate for second-generation sulfonylureas
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Table 3 Risk of AMI in rosiglitazone users compared with pioglitazone users, overall and subgroup analyses
Study (author,
year)
Overall RR (95 % CI) Subgroup analyses
Overall sensitivity
analysisa
Incident and prevalent cases New users
Sensitivity analysisa Sensitivity analysisa
Walker, 2008 [39] 0.82 (0.49–1.37)
Ziyadeh, 2009 [42] 1.35 (1.12–1.62)
Brownstein, 2010
[27]
1.70 (1.31–2.21) Not included Not included Not reported Not reported
Bilik, 2010 [26] 0.75 (0.33–1.67) Not reported Not reported




Juurlink, 2009 [33] 1.05 (0.90–1.23)
Graham, 2010 [30] 1.06 (0.96–1.18)
Winkelmayer, 2008
[41]
1.08 (0.93–1.25) Not reported
Koro, 2008 [34] 1.12 (0.99–1.26) Not reported Not reported Not reported
Gerrits, 2007 [29] 1.27 (1.06–1.52) Not included Not included Not included
Fixed-effects, sRR
(95 % CI)
1.12 (1.06–1.18) 1.09 (1.03–1.15) 1.13 (1.06–1.21) 1.08 (1.00–1.16) 1.10 (1.03–1.17) 1.08 (1.01–1.15)
Random-effects,
sRR (95 % CI)
1.13 (1.04–1.24) 1.09 (1.02–1.16) 1.14 (1.00–1.30) 1.07 (0.96–1.19) 1.10 (1.01–1.20) 1.08 (0.99–1.18)
Heterogeneity
statistics
τ2 = 0.01χ2 = 22.05,
df = 10 (P = 0.01)I2 =
55 %
τ2 = 0.00χ2 = 9.56,
df = 8(P = 0.30)I2 =
16 %
τ2 = 0.02χ2 = 21.74,
df = 8 (P = 0.005)I2 =
63 %
τ2 = 0.01χ2 = 9.26,
df = 6 (P = 0.16)I2 =
35 %
τ2 = 0.01χ2 = 11.06,
df = 7 (P = 0.14)I2 =
37 %
τ2 = 0.00χ2 = 8.47,
df = 6 (P = 0.21)I2 =
29 %
Not reported indicates that the study did not provide an estimate for that subgroup analysis. Not included indicates that the study was removed as part of the
sensitivity analysis
df degrees of freedom, RR relative risk, sRR summary relative risk
aSensitivity analysis: we excluded those studies with a combined high or unclear risk of bias for more than 30 % of the items in the RTI item bank
Table 4 Risk of AMI in rosiglitazone users compared with metformin users, overall and subgroup analyses
Study (author, year) Overall RR (95 % CI) Subgroup analyses
Overall sensitivity analysisa New users
Sensitivity analysisa
Loebstein, 2011 [35] Not estimable Not estimable Not estimable Not estimable
Walker, 2008 [39] 1.05 (0.67–1.66)
Tzoulaki, 2009 [38] 1.10 (0.87–1.39) Not reported Not reported
Dormuth, 2009 [28] 1.14 (0.90–1.44)
McAfee, 2007 [36] 1.19 (0.84–1.68)
Hsiao, 2009 [32] 2.09 (1.36–3.24) Not Included Not included
Brownstein, 2010 [27] 2.51 (1.98–3.17) Not Included Not reported Not reported
Fixed-effects, sRR (95 % CI) 1.44 (1.28–1.61) 1.13 (0.98–1.30) 1.24 (1.05–1.47) 1.14 (0.95–1.36)
Random-effects, sRR (95 % CI) 1.42 (1.03–1.98) 1.13 (0.98–1.30) 1.29 (0.99–1.67) 1.14 (0.95–1.36)
Hetrogeneity statistics τ2 = 0.14χ2 = 36.07, df = 5
(P < 0.00001)I2 = 86 %
τ2 = 0.00χ2 = 0.21, df = 3
(P = 0.98)I2 = 0 %
τ2 = 0.04χ2 = 6.62, df = 3;
(P = 0.09)I2 = 55 %
τ2 = 0.00χ2 = 0.17, df = 2;
(P = 0.92)I2 = 0 %
df degrees of freedom, RR relative risk, sRR summary relative risk
a Sensitivity analysis: we excluded those studies with a combined high or unclear risk of bias for more than 30 % of the items in the RTI item bank
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combining those studies (Additional file 1: Table 10e),
effect estimates were homogeneous across studies and
there was no evidence of heterogeneity (I2 = 0 %). The
sRR (95 % CI) was 1.22 (1.14–1.31). Two of the four
studies were included in the meta-analysis for only this
comparison [31, 37]. One was a field case–control study
with an imprecise RR estimate and 30 % or more of the
RTI-IB items assessed at high/unclear risk of bias. The
other was a nested case–control analysis that included
prevalent and new users. Three studies included only
first-ever AMI.
No impact on the meta-analysis results was found
after grouping the studies according to whether the
study period finished before or on 2007, started after
2007, or the study period included 2007 (data not
shown).
Publication bias
Examination of funnel plots did not suggest publication
bias, although the number of studies was small for some
comparisons. The funnel plots for studies evaluating the
risk of AMI in rosiglitazone users compared with pioglit-
azone users (n = 11), in rosiglitazone users compared
with metformin users (n = 7), and in rosiglitazone users
compared with sulfonylurea users (n = 5) are displayed
in Additional file 1: Figures 1e, 2e, and 3e.
Discussion
This systematic review of published observational stud-
ies on the risk of AMI associated with glitazones, met-
formin and sufonylureas in patients with T2DM
confirmed that studies in this field are very heteroge-
neous in exposure definition, comparison drugs, poten-
tial for biases secondary to design characteristics, and
study results. Therefore, summarising the scientific
evidence is challenging. The lack of a common reference
medication for evaluation of all potential exposures
across studies limited direct comparison of effect
estimates. Of the 31 studies included in our systematic
literature review, only 20 could contribute to the meta-
analysis, 17 for AMI and 3 for stroke.
Our summary effect estimates are compatible with a
small increase (around 10%) in the risk of AMI among
patients with T2DM using rosiglitazone compared with
the risk in those using pioglitazone. However, the degree
of heterogeneity present and results of the quality as-
sessment and sensitivity analyses indicate that caution
should be used when interpreting this result. Residual
confounding might be present in most observational
studies; therefore, small increases in risk are difficult to
interpret.
Studies in the stroke risk meta-analysis (n = 3) had
more homogeneous point estimates and quality assess-
ments than studies in the AMI meta-analysis (n = 11).
Considering that the lower limit of the 95 % CI is very
close to 1 and only 3 studies were available for meta-
analysis, the observed increase of 18 % in the risk of
stroke among patients using rosiglitazone compared
with those using pioglitazone should be considered
cautiously.
Similar words of caution apply to the comparisons of
rosiglitazone versus metformin and rosiglitazone versus
sulfonylureas. Although the sRRs indicate a 40 %
increase in risk of AMI for the first comparison and no
increase in risk for the second comparison, there was
strong evidence of heterogeneity for both comparisons,
and the sensitivity analyses produced effect estimates
closer to the null for the first comparison and further
from the null for the second comparison (from sRR of
0.99 to 0.92 in the subgroup analysis and to 0.82 in the
sensitivity analysis).
Results reported from the individual studies included in
other pioglitazone-versus-metformin and sulfonylureas-
versus-metformin comparisons produced more homo-
geneous results but involved few studies. The sRR for
pioglitazone versus metformin suggested no difference
in AMI risk for the two drugs, but the other com-
parison indicated a 24 % higher risk of AMI for sul-
fonylureas users than for metformin users.
In September 2014, we updated the literature search
using the original search terms in PubMed. Two new
studies were considered eligible and were reviewed
[43, 44]; they compared risk of AMI and of stroke for
rosiglitazone and pioglitazone. The updated effect es-
timates adding these 2 studies remained virtually un-
changed: sRR, 1.12 (95 % CI, 1.03–1.21) for AMI and
1.17 (95 % CI, 1.07, 1.27) for stroke.
The results of our meta-analysis are consistent with
results of two previous meta-analyses of observational
studies evaluating the risk of AMI comparing rosiglita-
zone and pioglitazone. The meta-analysis of 7 studies
conducted by Chen et al. [16] estimated a sRR of 1.17
(95 % CI, 1.04–1.32); I2 = 70 %. Loke et al. [11] con-
ducted a meta-analysis of 13 studies including patients
with T2DM, comparing rosiglitazone and pioglitazone
safety for AMI, congestive heart failure, and mortality.
For AMI, the odds ratio was 1.11 (95 % CI, 1.04–1.18) ;
I2 = 16 %. These estimated relative risks are similar to
our estimate. Differences in the studies included/excluded
between those two meta-analyses and our meta-analysis
might explain the differences in statistical heterogeneity.
Three meta-analyses of randomised controlled trials
(RCTs) have been published evaluating the safety of rosi-
glitazone for AMI and stroke and found that rosiglita-
zone increased the risk of AMI about 40 % compared to
control therapies or placebo [12–14]. The results of
those meta-analysis were not without controversy [45],
and there is evidence that they are sensitive to the
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statistical method used for pooling and the inclusion/ex-
clusion of different studies [46]. However, the available
evidence prompted the European Medicines Agency to
withdraw rosiglitazone from the market and the FDA to
place severe restrictions on rosiglitazone use [5]. In con-
trast, meta-analyses indicate a reduced risk of stroke
(about 20 %) for rosiglitazone compared to control ther-
apies. Although the 95 % CIs of those estimates include
the null effect, the inconsistency of the findings for AMI
and stroke is difficult to explain [46]. An independent
re-analysis of the RECORD trial data confirmed the
original results [9], that rosiglitazone did not increase
cardiovascular risk compared to a combination of met-
formin and sulfonylurea [47]; this has prompted the
FDA to ease some restrictions on rosiglitazone use.
Another re-analysis of clinical trial data has further
questioned the adverse cardiovascular safety profile of
rosiglitazone, reporting a hazard ratio of 0.77 for AMI
(95 % CI, 0.54–1.10) and of 0.36 (95 % CI, 0.16–0.86) for
stroke when comparing rosiglitazone with non-
thiazolidinedione use [7].
We did not identify any meta-analysis of RCTs directly
comparing rosiglitazone and pioglitazone with AMI as
the safety outcome of interest. Two meta-analyses of
RCTs comparing pioglitazone with control therapies or
placebo found reductions of around 20 % in the risk of
AMI or stroke, favouring pioglitazone, with 95 % CIs in
both cases including the null effect [48, 49].
For AMI and stroke we could not identify any published
meta-analyses of observational studies evaluating the
other drug comparisons included in this meta-analysis,
i.e., rosiglitazone or pioglitazone versus metformin, rosigli-
tazone versus sulfonylureas, and sulfonylureas versus met-
formin. Therefore, the current meta-analysis seems to be
the first one to review the results of studies including all
those comparisons.
This systematic review and meta-analysis has several
strengths. We included in the meta-analysis only studies
with a clear definition of the reported comparisons. Our
detailed evaluation of the quality of each reviewed study
and the sensitivity analyses helped us interpret meta-
analysis results of heterogeneous studies combined for
the purpose of evaluating the risk of AMI and stroke.
Our analyses included drug comparisons relevant to cli-
nicians and not included in previous meta-analyses.
As is true for every meta-analysis of observational
studies, the main limitation of this meta-analysis is the
heterogeneity in design and conduct of the primary
studies. Key drivers of this heterogeneity were the com-
plex array of treatment options, varying severity of dia-
betes, and varying outcome definitions. The studies that
combined medications (e.g., “any other treatment”) as
the reference group are of particular concern for this
and future meta-analyses for two main reasons. First,
“any other treatment” represents different treatments de-
pending on the study period and population, which de-
creases the applicability and comparability of results.
Second, results relative to such reference treatment may
not be useful for clinical decision makers who need to
choose between specific therapeutic alternatives. The re-
sults of this study show that methodological limitations
present in the original studies have an important role in
explaining the statistical heterogeneity found when com-
bining the individual study results in the meta-analysis.
When excluding those studies at high/unclear risk of
bias for 30 % or more of the items assessed by the RTI-
IB, heterogeneity was largely reduced in most of the
comparisons analysed. Overall results in those compari-
sons were sensitive to the exclusion of the studies more
prone to bias, which indicates lack of robustness in re-
sults when including such studies in the meta-analysis.
Few of the studies included accounted for severity of
diabetes; therefore, confounding by indication could be
present in the majority of within-study comparisons for
studies in this meta-analysis. Residual confounding
might be present in studies that failed to systematically
record or adjust for lifestyle factors. Few studies adjusted
for socioeconomic status, education, physical activity, or
BMI, which can all be associated with both treatment se-
lection and the development of outcomes. These and
other methodological limitations of the majority of the
studies included in this meta-analysis have been
reviewed in recent publications, which support the over-
all qualitative findings of this study [50, 51]. Since the
magnitude of the increased risks was rather small for
most of the comparisons, small residual confounding, if
present, could explain the small increases in the risk
estimates.
Evaluation of the risk of stroke was limited due to the
small number of published studies and inclusion of only
users of thiazolidinediones. Other limitations of this
meta-analysis had to do with the fact that dose and dur-
ation effects could not be evaluated for any comparison
due to the scarcity of data in the published studies and
the fact that the newest oral drugs for diabetes could not
be evaluated due to lack of studies.
Conclusions
In conclusion, sulfonylureas seem to increase the risk of
AMI by 24 % compared with metformin. With 3 small
studies and a corresponding lack of precision, results of
this meta-analysis suggest no difference in the risk of
AMI for pioglitazone compared with metformin. The
presence of heterogeneity in the meta-analysis results
precludes any conclusions on the risk of AMI for the
other comparisons evaluated. The quality assessment
with the RTI-IB and the sensitivity analyses indicate that
statistical heterogeneity might be attributable to the
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studies that were at the highest risk of bias according to
the RTI-IB. Future studies should consider the methodo-
logical pitfalls identified in the existing body of evidence.
Results from ongoing large multidatabase studies, care-
fully planned and conducted, are awaited and will help
to elucidate the risk of AMI and stroke associated with
the use of NIBGLDs.
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